We support clinical research as an integrated partner, from the first research question to the final publication. For sponsors, CROs, academic study groups and EU consortia who want a scientific peer, not a vendor.
In the PreCycle trial, the CANKADO PRO-React module was tested. Presented at the ASCO annual meeting and published in Annals of Oncology and Cancer Treatment Reviews.
Hazard ratio below 1 favours CANKADO-active. Boxes are point estimates, lines the 95% confidence interval; both primary endpoints are statistically significant. Hover a row for details. Progression-free and overall survival did not differ significantly between arms.
Partners gain an experienced scientific team that speaks the language of research. We support study design and grant applications, run the digital infrastructure and publish the results, as a proactive and co-creative partner at every stage.
Join us for a single phase or the full research cycle. We take on the roles that are often left unaddressed in the classical research ecosystem.
Research questions, hypotheses and study concepts, developed together.
Synopses, protocols, CRFs, ethics submissions and regulatory affairs.
EU grant applications such as Horizon Europe, taking on real responsibility as a committed consortium partner within the team.
Digital study design, platform configuration, hosting and operations.
Support of study sites, patients and project partners across countries.
Statistical analysis and biometry, then lead or co-authored publications and congress contributions.
The platform translates scientific questions into digital study designs, in clinical trials as well as in routine care. Its core engine is a CE-marked medical device.
A one-tap daily check-in serves as a low-burden trigger. Only when the system detects an anomaly does it request a CTCAE-based symptom checklist, and each grade is linked to a clear action instruction for the patient.
Clinical data (eCRF) and patient-reported data (ePRO) live in a single record. This enables AI integration, automated randomisation and cross-role designs that classical ePRO or EDC systems cannot support.
Validated ePRO, a standardised questionnaire engine (EORTC, EQ-5D, PROMIS), wearables and device integration, cardiac-safety monitoring, 18 languages and flexible EDC integration, all proven in large multicentre studies.
A representative selection across indications, phases and countries. Every study is publicly registered and independently published, so you can look it up rather than take our word for it.
| Study | Indication | Scale |
|---|---|---|
| CAPIcornNCT07281833 · Phase III | HR+/HER2− advanced BC | ~250 pts |
| CINDERELLANCT05196269 · EU HORIZON | Locoregional BC | ~1,000 pts 5 countries |
| DSMM XVIIEudraCT 2017-001616-11 · Phase III | Multiple myeloma | ~600 pts 55 sites |
| PAIPAFinvestigator-initiated · Phase IV | Atrial fibrillation | ~100 pts |
| PreCycleAGO-B + WSG · Phase IV | HR+/HER2− mBC | 499 pts 71 sites |
| ResPECTHorizon Europe | Breast cancer + depression | multi-country |
| RIBANNANCT06311383 · NIS | HR+/HER2− mBC | ~2,600 pts >260 sites |
| StomRayNCT04452032 · Phase II | Head & neck cancer | pilot study single centre (Brussels) |
| TOP-REALNCT07371585 · Phase II | HER2+ mBC | ~300 pts 60 sites |
| TP-IINCT03272477 · Phase II | HR+/HER2+ early BC | ~200 pts 40 sites |
“A long-standing and trusted partner in the design, implementation and operation of digital solutions for clinical studies, across complex international settings with thousands of patients.”
“CANKADO demonstrated a proactive and collaborative approach, continuously contributing to the platform's improvement beyond the initially defined scope.”
Our work is embedded in the research ecosystem, next to academic study groups, university hospitals, EU consortia and pharmaceutical sponsors.
Built in oncology, methodologically, regulatorily and technologically. Now running in cardiology, mental health, supportive and acute care, and human-performance research.
Partners build on infrastructure that is audit-ready from the first day of a study. Certification, medical-device conformity and data protection are engineered in from the start.
CANKADO began in 2014 as a research project and grew into a digital health research company. Owner-managed and founder-led, we unite colleagues of many nationalities and faiths across Europe, India and Latin America. That intercultural foundation is not a footnote. It shapes how we work, and it is why we describe ourselves as a research partner rather than a software vendor.
Tell us what you're working on. You'll hear back from the scientific team, usually within one working day. No funnel, no obligation.
CANKADO